Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19420195 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
Condition: Cystic Fibrosis
Interventions: Drug: AZLI 75 mg three times a day (TID);   Drug: Placebo three times a day (TID)

Indicates status has not been verified in more than two years